NHAS
Novo Holdings A/S Portfolio holdings
AUM $1.42B
1-Year Return
12.08%
This Quarter Return
+8.24%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.42B
AUM Growth
+$102M
(+7.8%)
Cap. Flow
+$35.9M
Cap. Flow
% of AUM
2.53%
Top 10 Holdings %
Top 10 Hldgs %
72.95%
Holding
34
New
3
Increased
10
Reduced
3
Closed
5
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
+$21.8M |
| 2 |
Apogee Therapeutics
APGE
|
+$19.5M |
| 3 |
Salesforce
CRM
|
+$15.6M |
| 4 |
VALN
Valneva
VALN
|
+$13.5M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$9.34M |
Top Sells
| 1 |
Amicus Therapeutics
FOLD
|
+$22.4M |
| 2 |
VERV
Verve Therapeutics
VERV
|
+$13.7M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$7.34M |
| 4 |
Insmed
INSM
|
+$4.5M |
| 5 |
Lexeo Therapeutics
LXEO
|
+$3.9M |
Sector Composition
| 1 | Healthcare | 48.34% |
| 2 | Technology | 15.92% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 2.98% |
| 5 | Industrials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$539B
| $316M | 22.28% |
1,038,550
| – | – |
|
2
Brookfield
BN
$104B
| $144M | 10.18% |
2,330,830
| – | – |
|
3
ASML
ASML
$341B
| $133M | 9.38% |
165,836
| – | – |
|
|
4
Salesforce
CRM
$231B
| $90M | 6.36% |
330,187
+57,386
| +21% | +$15.6M |
|
5
Mirum Pharmaceuticals
MIRM
$3.73B
| $76.3M | 5.39% |
1,500,055
+55
| +0% | +$2.8K |
|
6
Edgewise Therapeutics
EWTX
$1.44B
| $70.1M | 4.95% |
5,350,000
| – | – |
|
|
7
Insmed
INSM
$30.3B
| $68.4M | 4.83% |
680,000
-44,666
| -6% | -$4.5M |
|
8
Recursion Pharmaceuticals
RXRX
$2.08B
| $48.9M | 3.45% |
9,665,128
| – | – |
|
9
Crinetics Pharmaceuticals
CRNX
$3.18B
| $44.6M | 3.15% |
1,550,000
+275,000
| +22% | +$7.91M |
|
10
Alibaba
BABA
$377B
| $42.2M | 2.98% |
372,327
| – | – |
|
11
ArriVent BioPharma
AVBP
$769M
| $40.8M | 2.88% |
1,872,142
| – | – |
|
12
Merus
MRUS
$5.15B
| $39.5M | 2.78% |
750,000
-39,129
| -5% | -$2.06M |
|
|
13
BioMarin Pharmaceuticals
BMRN
$10.2B
| $36.3M | 2.56% |
660,000
+170,000
| +35% | +$9.34M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $34M | 2.4% |
264,956
+36,152
| +16% | +$4.63M |
|
15
Viridian Therapeutics
VRDN
$1.47B
| $33.3M | 2.35% |
2,380,000
+129,700
| +6% | +$1.81M |
|
16
Pharvaris
PHVS
$1.5B
| $30.4M | 2.14% |
1,725,000
| – | – |
|
17
Vaxcyte
PCVX
$4.02B
| $29.8M | 2.1% |
916,160
+1,160
| +0.1% | +$37.7K |
|
18
Celldex Therapeutics
CLDX
$1.63B
| $24.4M | 1.72% |
1,200,000
| – | – |
|
|
ZBIO
19
Zenas BioPharma, Inc. Common Stock
ZBIO
$924M
| $21.8M | 1.54% |
2,250,000
+35,033
| +2% | +$339K |
|
|
20
Enliven Therapeutics
ELVN
$1.1B
| $21.8M | 1.54% |
+1,084,432
| New | +$21.8M |
|
|
21
Apogee Therapeutics
APGE
$2.2B
| $19.5M | 1.38% |
+449,392
| New | +$19.5M |
|
|
CBLL
22
CeriBell, Inc. Common Stock
CBLL
$438M
| $16.9M | 1.19% |
900,000
+20,000
| +2% | +$375K |
|
|
VALN
23
Valneva
VALN
$767M
| $13.5M | 0.95% |
+2,375,000
| New | +$13.5M |
|
24
4D Molecular Therapeutics
FDMT
$318M
| $7.42M | 0.52% |
2,000,000
+50,000
| +3% | +$186K |
|
25
IO Biotech
IOBT
$121M
| $4.66M | 0.33% |
3,354,449
| – | – |
|